KRAS and neoplasm: It is now well established that patients with mCRC who have tumour KRAS mutations are unlikely to benefit from the addition of cetuximab to standard chemotherapy.25,26 However, in rectal cancer, the influence of KRAS mutation status on tumour response in the presence of radiation is unclear.